NCT07712445|RecruitingDMC
Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus
Platelet Membrane-coated Tenecteplase to Improve Thrombolytic Efficacy by Targeting Thrombus
Loading search results
Sponsor study identifier
observational
24
1 country
1
Study Start
June 30, 2026
Actual (reported)Primary Completion
July 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Tenecteplase (TNK) is the latest generation of specific thrombolytic drugs independently developed in China. This study aims to investigate the thrombolytic efficacy of platelet membrane-coated tenecteplase (PM-TNK) on human ex vivo arterial thrombi, and to explore the inhibitory effects of plasma from patients receiving antiplatelet therapy on its thrombolytic activity, thereby evaluating the future clinical application value of PM-TNK.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 30, 2026
Actual (reported)July 14, 2026
Actual (reported)July 17, 2026
Actual (reported)July 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Thrombolysis rate
Thrombolysis rate (%) = \[(initial clot weight - final clot weight) / initial clot weight\] × 100%.
60 min
1\. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots). 2.Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP). 3. Healthy volunteer (group 1) collected 40mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP). 4. Healthy volunteer (group 2) collected 9 ml venous blood samples (for platelet aggregation assay).
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
patients with suspected coronary artery disease scheduled for coronary angiography or interventional therapy； healthy volunteers.
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
First Submitted
July 14, 2026
First Posted
July 17, 2026
Study Start
June 30, 2026
Actual (reported)Primary Completion
July 30, 2026
Estimated (date passed)Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 17, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: